Sa Wang, MD
Hematology · Houston, TXNPI 1093798845
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,852 of the $27,123 with a category attached, or 73.2%. 6 manufacturers reported payments, led by Blueprint Medicines Corporation at 34.6% of the total. Reporting peaked in 2019 at $13,684 and has fallen 77.9% since, to $3,028 in 2025.
Across 18 payments — averaging $1506.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$9K
- Amgen$8K
- Stemline Therapeutics Inc.$6K
- GSK$4K
- AstraZeneca$149
- Seagen Inc.$33
Across 7 payments — averaging $22,142 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$117K
- GSK$38K
What the payments were for
- Consulting fees$5,82021%
- Speaking & faculty fees$19,85273%
- Travel & lodging$1,0894%
- Food & beverage$2181%
- Education$1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 5 | $9,391 |
| Amgen | 1 | $8,040 |
| Stemline Therapeutics Inc. | 8 | $5,610 |
| GSK | 1 | $3,900 |
| AstraZeneca | 2 | $149 |
| Seagen Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,123 in reported general payments places this provider in the 80th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Houston
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Swaminathan IyerHouston$50K
- Jing YeHouston$34K
- Senthil SukumarHouston$31K
- Uday PopatHouston$25K
- Rashmi Kanagal ShamannaHouston$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.